Alamar Biosciences, Inc. (ALMR) SEC Filings & Earnings Calls

Customer concentration

“During the three months ended June 30, 2026, there was one customer that represented 11 % of total revenue.” · word for word

Operating losses and negative cash flow

“We have incurred losses since inception, we expect to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and maintain cash flows from operating activities in excess of our capital investment requirements or to achieve and sustain profitability.” · word for word

Dependence on government funding

“Our business is significantly dependent on researchers who rely heavily on government funding, including NIH grants, and any reduction in, modification of the terms of or delay in such funding could adversely affect our sales and financial performance.” · word for word

Single source suppliers

“We are dependent on single source and sole source suppliers for some of the equipment, components and materials used in our products and in conjunction with our products, and the loss of any of these suppliers could harm our business.” · word for word

Trade tariff risk

“Enhanced trade tariffs, import restrictions, export restrictions, foreign regulations or other trade barriers may materially harm our business, financial condition and results of operations.” · word for word

Operating loss widening due to increased investments in headcount, infrastructure, and R&D.

“Operating expenses were $31.2 million for the second quarter of 2026, an 89% increase from $16.5 million for the corresponding prior-year period.” · word for word

Dependence on government funding for research customers could impact demand.

“dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions” · word for word

Loss of an independent director, but board size adjusted and committee filled, minimal operational risk.

“Board decreased the number of authorized directors to five and appointed Nicholas Naclerio to the Audit Committee.” · word for word

Operating loss increased to $12.3M from $8.6M YoY; net loss widened to $21.3M including convertible note remeasurement loss of $8.6M.

“Operating loss was $12.3 million for the first quarter of 2026, as compared to an operating loss of $8.6 million for the corresponding prior-year period. Net loss was $21.3 million... including a loss of $8.6 million related to the remeasurement of convertible notes.”

Dependence on research funding and academic/biopharma customers; potential impact from government funding reductions.

“Risks and uncertainties related to... dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions.” · word for word

History of losses and uncertainty of profitability

“We have incurred losses since inception, we expect to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and sustain profitability.” · word for word

Dependence on government research funding

“Our business is significantly dependent on researchers who rely heavily on government funding, including NIH grants, and any reduction in, modification of the terms of or delay in such funding could adversely affect our sales and financial performance.” · word for word

Intellectual property litigation

“Olink Proteomics AB and Olink Proteomics, Inc. v. Alamar Biosciences, Inc. ... The complaint alleges infringement of U.S. Patent No. 7,883,848 by Alamar’s manufacture, use, offer for sale, sale, marketing and/or distribution of its NULISA platform.” · word for word

Single source supplier dependency

“We are dependent on single source and sole source suppliers for some of the equipment, components and materials used in our products.” · word for word